BioSpace News Archive

Ayasdi announced it has been named a finalist at the Accenture HealthTech Innovation Challenge regional round recently held in Boston.

Citius Pharmaceuticals, Inc. (“Citius”) (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Chief Executive Officer, Mr. Myron Holubiak, will present at the Biotech Showcase Investor Conference.

Technavio analysts forecast the global pain management drugs market to grow at a CAGR of nearly 4% during the forecast period, according to their latest market research report.

An inventor from Thurmond, N.C., has developed the GERM BOMB, a modification to the current method of packaging a sanitizing/disinfectant spray so that it can sanitize an entire room/area.

Technavio analysts forecast the global urticaria drugs market to grow at a CAGR of over 10% during the forecast period, according to their latest market research report.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is updating the status of the U.S. phase 3 dry eye clinical trial (ARISE-3) and the U.S. trial in patients with epidermolysis bullosa (EB) based on a letter to stockholders issued today by its partner, GtreeBNT.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood’s planned separation which is on track to be completed in the first half of 2019.

Perception Health, a leading provider of healthcare market prediction software, announced today their inclusion on the new machine learning (ML) and artificial intelligence (AI) discovery page on AWS Marketplace.

Health Canada is set to publish a revised Canada Food Guide later this month

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the online publication in SAGE Open Medicine of the results of an investigator-sponsored Phase IIb clinical trial (MSK-001) evaluating Firdapse